R R

What Is Provenge?

Provenge is a prescription personalized cellular immunotherapy containing sipuleucel-T. It is approved to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. This means the cancer has spread beyond the prostate and continues to progress despite testosterone suppression, while causing few or no symptoms. Provenge is manufactured using immune cells collected from the individual patient through a procedure called leukapheresis. The cells are processed to stimulate an immune response against prostate cancer. Treatment consists of three intravenous infusions and is not traditional chemotherapy or a cure for advanced prostate cancer.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Provenge?

Provenge is a prescription personalized cellular immunotherapy containing sipuleucel-T. It is approved to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. This means the cancer has spread beyond the prostate and continues to progress despite testosterone suppression, while causing few or no symptoms. Provenge is manufactured using immune cells collected from the individual patient through a procedure called leukapheresis. The cells are processed to stimulate an immune response against prostate cancer. Treatment consists of three intravenous infusions and is not traditional chemotherapy or a cure for advanced prostate cancer.

read more about provenge ...

Copy this HTML:

Copy HTML Copied!

How Does Provenge Work?

Provenge uses a patient's own immune cells to stimulate an immune response against prostate cancer. Cells collected through leukapheresis are exposed during manufacturing to a protein combining prostatic acid phosphatase, an antigen expressed in prostate cancer tissue, with granulocyte-macrophage colony-stimulating factor. This process activates antigen-presenting cells that can help stimulate T-cell responses against cancer-associated targets. The finished product is infused back into the same patient. Provenge is designed to activate the immune system rather than directly destroy cancer cells through the mechanisms used by conventional chemotherapy.

Who Can Receive Provenge Treatment?

Provenge is approved for patients with metastatic castration-resistant prostate cancer who have no symptoms or only mild symptoms associated with their cancer. It is not intended as routine treatment for localized prostate cancer or patients whose advanced disease is causing substantial symptoms that require urgent relief. An oncology specialist assesses cancer history, disease progression, functional status, and eligibility for leukapheresis before treatment. Provenge is individualized for each patient and cannot be transferred to another person. Patients may continue other prostate cancer treatments as directed by their oncology team.

How Is Provenge Administered?

Provenge treatment involves three complete intravenous infusions administered approximately two weeks apart. Before each infusion, healthcare professionals collect the patient's immune cells through leukapheresis and send them for specialized manufacturing. Each personalized dose contains activated autologous immune cells and is infused back into the same patient. Premedication with acetaminophen and an antihistamine is recommended approximately 30 minutes before infusion to reduce infusion reactions. Patients are monitored during and after administration. If a scheduled infusion cannot be given, another leukapheresis procedure may be necessary before treatment can continue.

What Are the Side Effects and Warnings of Provenge?

Common adverse effects include chills, fatigue, fever, back pain, nausea, joint pain, and headache. Serious infusion reactions can involve breathing difficulties, dizziness, low blood pressure, and chest discomfort. Acute infusion reactions are more likely around the time of administration and require close monitoring. Cerebrovascular events, including stroke, have also been reported in treated patients. Leukapheresis can cause additional complications related to blood collection and vascular access. Patients should report fever, severe chills, breathing difficulties, chest pain, or sudden neurological symptoms immediately. Treatment must be administered only to the patient whose cells were collected.

Common Questions About Provenge

Is Provenge a type of immunotherapy?

Yes. Provenge is an autologous cellular immunotherapy made using the patient's own immune cells to stimulate an immune response against prostate cancer.

What type of prostate cancer does Provenge treat?

Provenge is approved for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

How many Provenge treatments are given?

A standard treatment course consists of three intravenous infusions administered approximately two weeks apart. Each infusion requires a separate cell collection and manufacturing process.

Is Provenge the same as chemotherapy?

No. Provenge is personalized cellular immunotherapy. It stimulates an immune response rather than directly attacking rapidly dividing cells as conventional chemotherapy does.

References

DailyMed - PROVENGE (sipuleucel-T) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8309b497-5d4e-4408-ac0c-2452c11c8a35. Date Accessed November 2, 2026.

PROVENGE (sipuleucel-T). U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/provenge-sipuleucel-t. Date Accessed November 2, 2026.

Sipuleucel-T. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/sipuleucel-t. Date Accessed November 2, 2026.

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. The New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/20818862/. Date Accessed November 2, 2026.

Sipuleucel-T Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a611025.html. Date Accessed November 2, 2026.